Prognostic value of the CAPRA clinical prediction rule: A systematic review and meta-analysis

BJU International

Volumn 111, Issue 3, 2013, Pages 427-436

  Meurs, Pieter ^a,c   Galvin, Rose ^a   Fanning, Deirdre M ^b   Fahey, Tom ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

CAPRA clinical predication rule; prognosis; prostatectomy; prostatic neoplasm; risk factors

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER OF THE PROSTATE RISK ASSESSMENT SCORE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; GLEASON SCORE; HUMAN; META ANALYSIS; METASTASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREND STUDY; VALIDATION STUDY;

DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874661881     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11400.x     Document Type: Article

References (23)

1. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A., Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010; 46: 3040-3052
2. National Cancer Registry. Cancer in Ireland 1994-2007. National Cancer Registry, 2009. Available at: http://www.ncri.ie/pubs/pubfiles/Summary-report- 19942007.pdf
3. Shariat S, Karakiewicz P, Roehrborn C, Kattan M,. An updated catalog of prostate cancer predictive tools. Cancer 2008; 113: 3075-3099
4. Cooperberg M., Prostate cancer risk assessment: choosing the sharpest tool in the shed. Cancer 2008; 113: 3062-3066
5. Ishizaki F, Hoque A, Nishiyama T, et al. External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy. Jpn J Clin Oncol 2011; 41: 1259-1264
6. Cooperberg M, Broering J, Carroll P,. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009; 101: 878-887
7. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco, Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938-1942
8. Moher D, Liberati A, Tetzlaff J, Altman D, Group P,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269
9. McGinn T, Guyatt G, Wyer P, Naylor C, Stiell I, Richardson W., Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA 2000; 284: 79-84
10. Loeb S, Carvalhal GF, Kan D, Desai A, Catalona WJ,. External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series. Urol Oncol 2010; Sept 3 [Epub ahead of print]
11. May M, Knoll N, Siegsmund M, et al. Validity of the CAPRA score to predict biochemical-recurrence-free survival after radical prostatectomy. Results from a European multicenter survey of 1,296 patients. J Urol 2007; 178: 1957-1962
12. Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW,. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology 2008; 72: 396-400
13. Cooperberg MR, Freedland SJ, Pasta DJ, et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 2006; 107: 2384-2391
14. Lughezzani G, Budäus L, Isbarn H, et al. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol 2010; 57: 562-568
15. Tamblyn DJ, Chopra S, Yu C, Kattan MW, Pinnock C, Kopsaftis T,. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer. BJU Int 2011; 108: 51-56
16. Cooperberg M, Hinotsu S, Namiki M, et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009; 27: 4306-4313
17. Halverson S, Schipper M, Blas K, et al. The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: evaluation and optimization in patients at higher risk of relapse. Radiother Oncol 2011; 101: 513-520
18. Cooperberg M, Vickers A, Broering J, Carroll P,. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 2010; 116: 5226-5234
19. Cooperberg M, Hilton J, Carroll P,. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011; 117: 5039-5046
20. Keogh C, Wallace E, O'Brien KK, et al. Optimized retrieval of primary care clinical prediction rules from MEDLINE to establish a Web-based register. J Clin Epidemiol 2011; 64: 848-860
21. Galvin R, Geraghty C, Motterlini N, Dimitrov BD, Fahey T,. Prognostic value of the ABCD(2) clinical prediction rule: a systematic review and meta-analysis. Fam Pract 2011; 28: 366-376
22. Keogh C, Wallace E, Dillon C, Dimitrov BD, Fahey T,. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 2011; 106: 528-538
23. Aalbers J, O'Brien KK, Chan WS, et al. Predicting streptococcal pharyngitis in adults in primary care: a systematic review of the diagnostic accuracy of symptoms and signs and validation of the Centor score. BMC Med 2011; 9: 67. Available at: http://www.biomedcentral.com/content/pdf/1741-7015-9-67. pdf